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Abstract: COPD is associated with significant morbidity and is one of the leading causes of 
death worldwide. Periods of exacerbation, the acute worsening of symptoms, are interspersed 
throughout the disease’s natural history and can result in increased treatment burden and hos-
pitalization for patients with COPD. The frequency of exacerbations varies between countries, 
with both epidemiological studies and randomized controlled trials (RCTs) showing significant 
differences in observed prevalence rates. Differences in study design and the healthcare setting 
are likely to contribute to differences in exacerbation frequency, however the perceived rate 
of exacerbations in Japan is currently lower then the rest of the world. This review identified 
nine cohort studies and five RCTs that reported COPD annual exacerbation rates in Japan in 
the ranges of 0.1–2.1 and 0.33–1.79, respectively. The difference in exacerbation rate between 
studies appeared greater than the difference between Japan and Western countries, likely because 
of disparities between settings, design, and inclusion criteria. Of these, only one (Understanding 
the Long-Term Impacts of Tiotropium) had uniform inclusion criteria across different regions. 
This study found that the annual rate of exacerbation events per patient in Japan was 0.61, 
compared with 0.85 worldwide in the placebo groups. This review summarizes the published 
rates of COPD exacerbations in Japan and the rest of the world and explores the hypotheses 
as to why rates in Japan might be lower than other countries. These include access to medical 
care, variance in the associated morbidity profile, environmental factors, diagnostic crossover 
with related diseases, and differences in study design (including the underreporting of COPD 
exacerbations in Japan). Understanding the reasons why COPD exacerbation rates appear lower 
in Japan could help clinicians to recognize and modify treatment behaviors, which may lead to 
improved patient outcomes in all populations.
Keywords: COPD, exacerbation rate, asthma-COPD overlap, Japan
Introduction
COPD is associated with significant morbidity and mortality, with 2020 estimates 
showing that it is likely to become the third most common cause of death 
worldwide.1 Impairments are present in the health status of patients with COPD 
of all severities, even in those with mild airway obstruction.1 The natural history 
of COPD is interspersed by exacerbations – the acute worsening of symptoms.2 
Importantly, morbidities often manifest alongside COPD exacerbations, and 
they are known to have a negative impact on patients’ quality of life, FEV
1
, the 
likelihood of hospitalization, readmission, health status, and disease progression.1,3 
A Pan-European study of patients with COPD found that they recorded mean health-
related quality of life (HRQL) scores that were over twice the clinically significant 
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threshold for being considered “impaired” (as shown using 
the St George’s Respiratory Questionnaire-COPD specific 
[SGRQ-C]),1 with those patients suffering an exacerbation 
having a worse SGRQ-C score compared with those with 
stable disease. This finding supports those from another 
study which demonstrated that a single nonhospitalized 
exacerbation can have a large and long-lasting effect on 
patient’s health status.4
Exacerbations of COPD have a complex pathogenesis 
with viral or bacterial respiratory infections being the prime 
triggers, although pollution and climate are also known to 
play a role.3 Exacerbations are associated with increased 
inflammation of the airways, production of mucus, and the 
trapping of gas.3 Ultimately, COPD exacerbations are associ-
ated with significant mortality.3
Although the COPD burden is global, an analysis of 
the rate of exacerbations reported in both epidemiological 
studies and randomized controlled trials (RCTs) of patients 
with COPD demonstrates that it is not uniform worldwide. 
However, differences between studies are likely to be sig-
nificantly influenced by the cohort setting (eg, primary vs 
secondary or tertiary care) and the specific inclusion criteria. 
For example, the multicenter, international, longitudinal, 
observational ECLIPSE study (N=2,138) conducted in 
secondary and tertiary care in North America, Europe, and 
New Zealand reported an annual exacerbation rate of 1.2 per 
patient,2 while the Salford Lung study (N=2,799), an RCT 
of fluticasone furoate–vilanterol for COPD conducted in 
primary care in the UK, reported an exacerbation rate of 2.0 
in the 12 months prior to randomization.5 Further variation 
can be seen in the DACCORD study (an ongoing real-world, 
noninterventional, community-based study in Germany 
[N=3,974]), which reported an annual COPD exacerbation 
rate of just 0.4 during the first year of follow-up.6
In contrast to observed Pan-European and North 
American exacerbation rates, COPD exacerbations appear 
to be generally less frequent in Japan compared with the rest 
of the world.7 Notably, there are currently no studies that are 
directly comparable in design or inclusion criteria between 
Japan and the rest of the world. However, the UPLIFT trial, 
which was a multicenter study (N=5,992) of tiotropium use in 
30 countries in patients with COPD,8 included patients from 
Japan. A subgroup analysis of patients enrolled to the control 
arm in the UPLIFT trial showed that the exacerbation rate in 
the Japanese cohort (n=100) was lower than both the Asian 
and the overall study cohorts (mean number of exacerbations 
per patient year was 0.61 [Japanese cohort] compared with 
0.92 [Asian cohort] and 0.85 [total UPLIFT cohort]).7
Understanding the differences in exacerbation rates 
between Japan and other regions of the world may elucidate 
factors that are important for the effective management of 
patients with COPD. The aim of this review is to discuss 
the frequency of, and the potential factors affecting, COPD 
exacerbations in Japan compared with other Asian and 
Western countries.
Literature search and review 
methodology
During the literature review and article selection, we used 
PubMed searches to identify original research articles that 
were published up to May 15, 2017, using the search terms 
“COPD” AND “Japan” AND “exacerbation”. Overall, 
161 papers were initially identified; screening of the titles and 
abstracts for relevance identified 50 papers of interest.
A further screening of the full text of these 50 papers 
identified a total of 14 studies which met the following 
criteria and are discussed in this review: 1) studies that 
recruited Japanese patients and for which the incidence of 
exacerbations as a rate per person per year for the Japanese 
population living in Japan was available and 2) studies for 
which the incidence of exacerbations in a Japanese popula-
tion was available from an unpublished source (one study, 
COSMOS-J).9 For studies that had multiple associated 
papers, the paper with the most recent data, patients with 
more general COPD, and data on Global initiative for chronic 
Obstructive Lung Disease (GOLD) stage was chosen (in 
order of priority).
Overall, the search identified 9 COPD10–18 cohort studies 
and 5 pharmaceutical company-sponsored RCTs.7,9,19–21 As 
there can be some significant differences in population char-
acteristics between cohort studies and RCTs, findings from 
these two study types are summarized separately.
Reported COPD exacerbation rates 
in Japan
Cohort studies
Overall, nine cohort studies reported exacerbation rates in 
patients with COPD in Japan (Table 1). A summary of the 
study characteristics, key inclusion criteria and patient demo-
graphics, definitions of COPD exacerbation, and incidence 
of exacerbations (a rate per person per year) is presented in 
Table 1. The study design, study center, recruitment period, 
inclusion criteria, and detailed definition of COPD exacer-
bation are shown in Table S1, but the number of patients is 
only shown in Table 1.10–18
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Table 1 Summary of exacerbation rates and key patient characteristics from cohort studies detailing COPD exacerbation rates in 
Japan10–18
Cohort  
(study)
Inclusion  
criteria
Definition  
of COPD  
exacerbation
N Patient baseline characteristics Incidence of  
exacerbations  
(per person  
per year)a
Age  
(years)a
Female 
(%)
GOLD  
stage III/IV 
(%)
ICS use 
(%)
Kyoto cohort 
(Takahashi et al, 2012)16
•	 Male patients with COPD
•	 No exacerbation history 
criteria
Symptom-based 
(diary)
93 73 0 30/5 40.8 0.8, 1.2b
Nippon cohort
(Motegi et al, 2013)12
•	 Patients with COPD 
(GOLD)
•	 40 years of age
•	 Current or ex-smokers 
(20 pack-years)
•	 No exacerbation history 
criteria
Symptom-based 
(diary)
183 71.4±8.7 7.1 33.9/9.8 NR 0.57
Kitano cohort 
(Takemura et al, 2013)18
•	 Patients with COPD 
(GOLD)
•	 Current or ex-smokers 
(10 pack-years)
•	 No change in medication 
for 3 months before study
•	 No exacerbation history 
criteria
event-based 
(medical 
records)
55 69±8 27.3 16.4/5.4 100 Baseline:  
1.5±1.6;  
Year 4: 0.8±1.4
Hokkaido cohort 
(Suzuki et al, 2014)15
•	 Patients with COPD 
(GOLD)
•	 40 years of age
•	 Current or ex-smokers 
(10 pack-years)
•	 No exacerbation 1 month 
prior to study
Symptom-based 
and event-
based
268 70±8 6 24.3/4.9 NR 0.78±1.16,c 
0.24±0.47,c 
0.20±0.43,c 
0.13±0.28,c  
0.06±0.19c
Saitama cohort
(Kurashima et al, 2015)10
•	 Male patients with COPD
•	 No exacerbation history 
criteria
event-based 65 70.8±6.4 0 NR 50.8 0.67±0.85
CAP study
(Matsunaga et al, 2015)11
•	 Clinical diagnosis of 
COPD
•	 40–95 years of age
•	 No exacerbation in the 
4 weeks prior to the 
survey
event-based 1,168 72.1±8.3 11.4 26.0/7.7 6.8 0.53±0.87
Kurume cohort (Natori 
et al, 2016)13
•	 Patients with COPD 
(GOLD)
•	 No exacerbation 4 weeks 
prior to study entry
Symptom-based 123 64.3, 
67.8, 
68.5, 
70.4c
20.7, 
10.5, 
14.3,  
0c
22.8/7.3 3.5, 
15.8, 
25.0, 
11.1d
0.1±0.2, 0.9±0.1, 
1.4±0.2, 2.1±0.4d
Keio cohort (Sato et al, 
2016)14
•	 Patients with COPD 
(spirometry)
•	 No exacerbation 
for 1 month prior 
to enrollment
event-based 311 72.6±8.1 6.8 23.2/5.8 26.6, 
32.8, 
47.2e
0.28f
Chiba cohort 
(Takayanagi et al, 
2017)17
•	 Patients with COPD 
(ATS/eRS)
•	 Current or ex-smokers
•	 No exacerbation history 
criteria
event-based 58 69.7±7.3 12.1 15.5/6.9 NR 0.75  
(1.5±0.9/2 years)g
Notes: aData are presented as mean±SD (where available) unless otherwise stated; bdata represent patients with high IgG (0.8 events/year) and normal IgG (1.2 events/
year); cdata represent symptom-based due to subjective complaints (0.78±1.16), symptom-based by strict definition, confirmed by CRC (0.24±0.47), event-based due to 
requiring prescription change (0.20±0.43), event-based due to requiring antibiotic treatment (0.13±0.28), and event-based due to requiring hospital admission (0.06±0.19); 
ddata represent GOLD stages I–Iv; edata represent nonexacerbators, mild exacerbators, and moderate/severe exacerbators; fmoderate or severe exacerbations; gone-year 
data calculated from 2-year data.
Abbreviations: ATS/eRS, American Thoracic Society/european Respiratory Society recommendations; CRC, Clinical Research Coordinator; GOLD, Global initiative for 
chronic Obstructive Lung Disease; GORD, gastro-esophageal reflux disease; ICS, inhaled corticosteroid; NR, not reported.
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Across all nine cohort studies, exacerbation rates ranged 
0.1–2.1 exacerbations per patient-year (Table 1).10–18 In gen-
eral, COPD severity appeared to account for much of the 
variability, with exacerbation rates varying according to 
GOLD classification and modified Medical Research Council 
grade.11,13 For studies that assessed the whole COPD popula-
tion, without respect to COPD severity, exacerbation rates 
ranged 0.24–0.8 events per year.10,12,14,15,17,18 Interestingly, 
in the Kitano cohort study, which aimed to improve inhaler 
technique and adherence, exacerbation rates decreased from 
1.5 at baseline to 0.8 by Year 4.18 In studies whose inclusion 
criteria specified no exacerbations in the 4–6 weeks prior to 
study entry, exacerbation rates were 0.24 and 0.28 events per 
person per year.14,15 Overall, when assessing the whole COPD 
population, it appears that exacerbation rates in Japan are lower 
than those seen in the ECLIPSE study (1.2 events per year)2 
and a large database cohort study of primary care patients in 
the UK (0.9 events per year).22 However, the difference in 
exacerbation rate between studies appeared greater than the dif-
ference between Japan and Western countries, likely because 
of disparities between settings, design, and inclusion criteria.
Randomized controlled trails
A summary of exacerbation rates in the five identified RCTs 
that enrolled patients in Japan is presented in Table 2. The 
study design, study center, recruitment period, inclusion 
criteria, and detailed definition of COPD exacerbation are 
shown in Table S2. The number of patients is only shown 
in Table 2.7,9,19–21 Overall, the reported COPD exacerbation 
rates were 0.33–1.79.7,9,19–21 Intra- and interstudy variations 
in COPD exacerbation rates occurred depending on treat-
ment drug vs placebo, and the studies differed in inclusion 
and exclusion criteria, with two of the five studies excluding 
patients with prior exacerbation history 1 week19 and 4 weeks7 
before enrollment. The subgroup analysis performed on the 
UPLIFT study population shows that exacerbation rates in 
the placebo group and the treatment group were lower for the 
Japanese subgroup (0.61 and 0.37 per patient-year) compared 
with the Asian (0.92 and 0.68 per patient-year) and overall 
(0.85 and 0.73 per patient-year) populations (Figure 1A).7 
As UPLIFT has the same inclusion criteria across the different 
populations, this is currently the best evidence available that 
can provide a comparison between the Japanese population 
and those of other countries.
Patient characteristics affecting exacerbation 
frequency
Difference in exacerbation frequency might be affected by 
population characteristics (eg, GOLD severity, body mass index 
[BMI], and age). In terms of GOLD severity, across multiple 
cohort studies and RCTs, it appears that patients from Japan 
have less severe COPD than patients from other countries. For 
example, 0%–9.8% of patients had very severe COPD in studies 
from Japan7,9,19–21 compared with 12% (GOLD stage IV) in the 
Asian cohort of the UPLIFT trial and 9% in the total cohort.7
Across four cohort studies reporting HRQL life outcomes 
in Japan, SGRQ total scores varied from 23.8 to 40.6.14,15,18,23 
Data from the UPLIFT study suggested that patients from 
Japan have better health status compared with the rest of the 
world (SGRQ total score at baseline: 40.5 vs 45.9, respectively) 
and other Asian countries (40.5 vs 44.4, respectively).7 This is 
despite the observation that patients from Japan tended to be 
older and have lower BMI compared with Western counter-
parts. In the cohort studies and RCTs reported here, the mean 
age of Japanese patients was 64–75 years (Tables 1 and 2) 
which is comparable but a little lower than Western patients 
(64–67 years), but BMI was clearly lower at 19–24 kg/m2 
compared to 26–28 kg/m2 among Western patients.2,7,12–14,17 in 
ECLIPSE, Salford Lung study, DACCORD, and UPLIFT.2,5–7 
Older age and lower BMI have been shown to be associated 
with poorer prognosis in COPD.15,24,25
In summary, reported COPD exacerbation rates might 
be lower in Japan than other Asian countries and the rest of 
the world. Moreover, in general, COPD severity is reduced, 
and health status scores are slightly less impaired in Japan 
compared with other Asian and Western countries; these 
could be factors linked to the lower reported frequency of 
exacerbation.
Potential factors affecting the rate of 
COPD exacerbations in Japan
Intrinsic and extrinsic factors
Many contributory factors may influence the low reported 
COPD exacerbation rate in Japan. To best understand the 
potential reasons for the observed differences, we must 
consider hypotheses relating to both intrinsic and extrinsic 
factors that could act upon the Japanese population in a dif-
ferent manner to other countries.
Intrinsic factors in this case relate to variables that are 
specific to the people of Japan, namely the genetic profile 
and ethnicity of the population. To our knowledge, no data 
linking genetic factors unique to the Japanese population and 
COPD exacerbations have been identified. Furthermore, we 
would suggest that intrinsic factors are unlikely to account 
for the difference in COPD exacerbation rate since, in the 
UPLIFT study, countries with populations that are of pre-
dominantly Asian ethnicity (eg, Singapore and Taiwan) all 
had observed trends in exacerbation rates that were different 
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Table 2 Summary of exacerbation rates and key patient characteristics from RCTs detailing COPD exacerbation rates in Japan7,9,19–21
Study Inclusion criteria 
relating to disease 
severity and 
exacerbation history
Definition 
of COPD 
exacerbation
Interventions N Patient baseline characteristics Incidence of 
exacerbations 
(per person 
per year)a
Age 
(years)a
Female 
(%)
GOLD  
stage III/IV (%)
ICS use 
(%)
Furumoto 
et al 
(2008)20
•	 Patients with chronic 
lung disease including 
COPD, with sequelae of 
pulmonary tuberculosis
•	 Previous exacerbations
Symptom-
based
Pv+Iv
Iv alone
87
80
69.0±9.0 36.5 NR NR 0.53 (COPD 
population;  
n=55)
Sasaki et al 
(2009)21
•	 Patients with COPD
•	 No exacerbation 
criteria for inclusion or 
exclusion
Symptom-
based
Lansoprazole 
15 mg/day
Placebo
50
50
74.9±8.9
74.8±7.5
6
4
34/6
40/2
26.0
24.0
0.34±0.72
1.18±1.4
Fukuchi et al 
(2011)7
•	 Patients with COPD
•	 Post-Fev1% pred: 70%
•	 Post-Fev1/FvC: 70%
•	 No exacerbation 
4 weeks before 
screening
Symptom-
based
TIO
Placebo
50
50
66.9±6.0
68.0±5.5
8
4
48/6
56/0
26.0
24.0
0.37 (95% CI: 
0.26–0.51)
0.61 (95% CI: 
0.46–0.81)
Fukuchi et al 
(2016)19
•	 Patients with COPD
•	 Post-Fev1% pred: 80%
•	 Post-Fev1/FvC: 70%
•	 1 exacerbations in the 
previous year
•	 No exacerbation 
7 days prior to drug 
administration
Symptom-
based
Lysozyme 
270 mg/day
Placebo
202
204
68.8±9.3
70.3±7.2
9.4
8.8
36.1/5.0
29.4/5.4
8.4
7.4
1.4±1.5
1.2±1.4
Jones et al 
(2016)9
•	 Patients with COPD event-based, 
symptom-
based
FP/SAL 
TIO
405 68.3±7.0 5 NR NR 1.79 (95% CI: 
1.56–2.05) 
(eXACT criteria)
0.33 (0.24–0.44) 
(physician 
reported)
Notes: aData are presented as mean±SD unless otherwise stated. TIO, tiotropium 18 µg once daily.
Abbreviations: EXACT, Exacerbations of Chronic Pulmonary Disease Tool; FP/SAL, fluticasone propionate/salmeterol 250/50 µg twice daily; GOLD, Global initiative for 
chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; IV, influenza vaccine; pred, predicted; PV, pneumococcal vaccine; RCT, randomized controlled trial.
Figure 1 exacerbations in the (A) UPLIFT study7 and (B) ACCeSS study.30
Abbreviation: CvD, cardiovascular disease.
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from that of Japan.7 Another intrinsic factor may be behav-
ioral characteristics, with Japanese patients less likely to 
report worsening symptoms on health status questionnaires; 
however, this is an observational hypothesis with no scientific 
evidence. The lower SGRQ score (40.5±13.6 in Japanese 
vs 45.9±17.1 in overall populations), in the UPLIFT study, 
regardless of their similar FEV
1
 (% predicted) (38.6±11.5 in 
Japanese vs 39.4±12.0 in overall populations), might reflect 
that kind of behavioral characteristics in Japanese. We must 
also be mindful that a small risk exists for these data to be 
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confounded by a minority of patients who overreport their 
symptoms, some instances of which have been reported in 
Japanese studies.15
Multiple extrinsic factors are potentially involved in 
explaining the lower exacerbation rate in Japan. In this con-
text, these specifically relate to medical and environmental 
variables that are measurably different in Japan compared 
with other populations. Some of these key factors are out-
lined below, alongside our hypotheses as to how these might 
influence the reported exacerbation rate.
Access to medical care
The intensity of medical care generally relates to physician 
visit frequency. On average, Japan has nearly twice that of the 
Organization for Economic Co-operation and Development 
(OECD) average physician consultations and over three times 
as many as Sweden (12.9 consultations per capita vs 6.6 and 
2.9, respectively).26 This could explain, in part, the low rate of 
hospital admissions for COPD in Japan compared with other 
Asian and western countries.26 In 2013, there was a 17-fold 
difference in age–sex standardized hospital admission rates 
for COPD across the 35 OECD countries, with Japan hav-
ing the lowest rates (∼20–25 per 100,000 population), com-
pared with Hungary and Ireland who had the highest rates 
(∼350–400 per 100,000 population).27 Another explanation 
for the low admission rate is the diagnosis of bacterial exac-
erbations as pneumonia, leading to earlier treatment with 
antibiotics and preventing the need for hospitalization. These 
diagnoses might be higher in Japan than in other countries.
The studies identified in this review show clear differences 
in the characteristics of the Japanese COPD patient popula-
tion and that of Western populations; in general, Japanese 
patients with COPD have lower SGRQ and COPD assessment 
test scores, have lower modified Medical Research Council 
scores, are older, have lower BMI, and majority are male.2,5–7 
Several of these variables can be influenced by effective and 
regular physician monitoring of the condition. The reduced 
exacerbation rate in Japan may be a result of closer manage-
ment of the patient, resulting in increased disease stability. 
In this respect, Japan appears to some to be leading the world 
in effective COPD management. Longitudinal changes in the 
SGRQ scores during the 5-year Hokkaido COPD cohort study 
(N=261) showed that some patients had sustained improve-
ment in symptoms over time.28,29 Hence, there may have been 
a change in the natural history of COPD in Japan during 
the last decade, with fewer patients showing a progressive 
decline; this may have been impacted by the introduction of 
effective inhaled therapies over this period.
We should note that the lower COPD exacerbation 
rate reported in Japan is similar to that seen in the German 
population (DACCORD study).6 However, the baseline 
demographics in each study population, such as age, BMI, 
and gender, were different and the similar exacerbation rates 
cannot be easily attributed to an obvious variable. Therefore, 
similarities may exist in extrinsic factors affecting the two 
country populations and should be investigated further. 
Currently, there are no studies in a Japanese population that 
have inclusion criteria similar to DACCORD, and as such 
a comparison of these rates with other studies in Japan is 
not appropriate. The primary care-based ACCESS study in 
European patients with COPD, with and without cardiovas-
cular disease (CVD), reported an acute exacerbation rate 
of 0.63 per patient per year (Figure 1B).30 This is similar 
to the exacerbation rate reported for the Japanese cohort in 
the UPLIFT study (0.61 per patient per year).7 However, it 
should again be noted that baseline characteristics of the two 
study populations were different: patients in ACCESS had 
a mean age of 66.1 years, mean BMI 27.2 kg/m2, 70% were 
male, 26.6% were GOLD stage III, and 6.3% were GOLD 
stage IV,30 while those in the Japanese cohort of UPLIFT 
had a mean age of 68.0 years, mean BMI 20.7 kg/m2, 96% 
were male, 56% were GOLD stage III, and none were 
GOLD stage IV.7
There is also the potential that regular access to medical 
care can influence the behavior of patients in Japan experi-
encing a mild exacerbation. We suggest that the reporting 
of a COPD exacerbation requires three things: first, that the 
patient recognizes the significance of the deterioration in 
their condition; second, that the patient reports this to their 
physician; and finally, that the physician makes the correct 
diagnosis of COPD and COPD exacerbation. As they know 
they have a regular scheduled physician visit coming up 
soon, it is possible that following an exacerbation, patients in 
Japan may be more likely to wait rather than seek immediate 
treatment, to see if their symptoms resolve spontaneously, 
resulting in underreporting of COPD exacerbations. This 
hesitancy to seek treatment may be compounded by the fact 
that the severity of COPD in Japanese patients is lower on 
average.
Associated morbidities
It is possible that a lower level of associated respiratory 
comorbidities in Japan may be a factor that contributes to 
lower COPD exacerbation rates. For example, the use of 
home-based long-term oxygen therapy (LTOT) for COPD 
has not increased in Japan (2005, 48% of all LTOT; 2010, 
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45% of all LTOT),31 which potentially may reflect a reduc-
tion in COPD severity.
As already highlighted, there is a trend for patients with 
COPD in Japan to be older than those in other countries.7 
But despite the aging population, data from the Japanese 
Ministry of Health and Welfare demonstrate that the COPD 
mortality rate has decreased steadily from a 1995 peak of 13.2 
men and 4.7 women per 100,000, 9.7 and 2.5, respectively, 
in 2015.32 This tendency is particularly noticeable in the 
age-adjusted mortality rate using the 1985 model population 
as the standard population (from a 1995 peak of 11.6 men 
and 2.4 women per 100,000, 3.5 and 0.6).33 Moreover, the 
percentage of COPD mortality among people 80 years of 
age within total COPD mortality is 70% and increasing 
year-on-year, indicating that the Japanese population is 
living longer with more stable disease. Mortality rates are 
also lower in Japan (6.0%–8.0%) when directly compared 
with the overall UPLIFT study population (12.8%–13.7%) 
as well as the Asian subpopulation (15.8%–21.9%).7 This 
reduction in COPD mortality rate in Japan is associated with 
a corresponding reduction (40%) in disability-adjusted 
life years (DALYs), indicating that much of the burden of 
COPD is either preventable or treatable with affordable 
interventions.34
environmental factors hypothesis
Ambient air pollution contributes substantially to the global 
burden of disease, compared with the global air pollution, air 
particle mass in Japan is much lower,35 which may play a role 
in the reduced frequency of COPD exacerbation. A decreas-
ing trend in adult smoking rate might also affect the COPD 
exacerbation rate. In 1989, the adult smoking rate was 55.3% 
of Japanese men and 9.4% of Japanese women. Those rates 
gradually decreased to 32.1% and 8.5% by 2014.36 In addition, 
the current smoker rate in clinical studies tends to be lower 
compared with other countries. In the UPLIFT study, only 
19.0% of Japanese patients were current smokers, compared 
with 29.6% of patients in overall populations.7 This might 
suggest that Japanese COPD patients are more likely to stop 
smoking on the advice of their doctors after their diagnosis. 
Moreover, the national diet of a country is well characterized 
as being influential over the health profile of its citizens. To 
that point, a recent meta-analysis (N=81,720) of a prudent 
Japanese diet characterized by high intake of vegetables, 
fruit, soy products, potatoes, seaweed, mushrooms, and fish 
was significantly associated with a reduced risk of both all-
cause and CVD mortality.37 A Westernized Japanese diet, 
more prevalent in the population since the 1970s, consisting 
of an increased intake of meat, processed meat, bread, and 
dairy products, was also inversely associated with risk of 
all-cause, cancer, and CVD mortality.37
COPD diagnosis
It is important to note that current Global Initiative for 
Asthma guidelines highlight that distinguishing COPD and 
asthma can be problematic due to patients presenting with the 
clinical features of both conditions.38 Importantly, asthma-
COPD overlap (ACO) does not represent a single disease 
entity,38 and patients can have asthma with COPD and vice 
versa. Although initial recognition of ACO can be made in 
primary care settings, referral for diagnostic confirmation 
should be made as patient outcomes are often worse than 
for asthma or COPD alone.38
Importantly, these evolving guidelines and prescribing 
practices for the management of COPD and asthma may 
contribute to lower reports of exacerbation rates in Japan, 
owing to diagnostic transfer of patients. In the UPLIFT study, 
only 25.0% of Japanese patients were receiving inhaled cor-
ticosteroids at baseline, compared with 61.6% and 61.7% of 
patients in the Asian and overall populations, respectively.7 
This potentially reflects the likelihood for sharp distinc-
tions in the diagnoses between asthma and COPD in Japan, 
removing those patients with overlapping and more serious 
symptoms from Japanese study cohorts. This is important 
because patients with ACO are more likely to have exac-
erbations than patients with a predominantly emphysema 
phenotype alone.39
Another possibility is that, because Japanese physicians 
utilize computed tomography scans for the diagnosis of 
COPD, they actively look for the presence of emphysema. 
In the absence of emphysema, but in the presence of air flow 
limitation, Japanese physicians would likely make a diagno-
sis of asthma, thereby meeting one of the exclusion criteria 
for COPD studies. As such, Japanese studies are potentially 
reflective of more homogenous, emphysema-dominant 
patient populations with less complex and severe disease.
However, recent studies confound this conclusion. Cohort 
data from the USA have shown that patients with asthma-
COPD have worse outcomes than patients with COPD but 
without asthma,39 but a 10-year follow-up of the Hokkaido 
cohort suggests a different picture.40 The Hokkaido cohort 
included 268 patients with COPD and a clinical opinion (by a 
respiratory specialist) of not having asthma.15,40 However, in 
a retrospective analysis of the Hokkaido cohort,40 133 (50%) 
patients had the presence of asthma-like features confirmed 
(blood eosinophil counts 300 cells/µL, bronchodilator 
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reversibility, or atopy). However, it has to be recognized that 
asthma was excluded in these patients using markers that are 
not only specific to asthma but also seen in COPD.39
Study design: reporting of COPD 
exacerbations varies between countries
Ultimately, considerations relating to study design and 
COPD diagnosis highlight an important point relating to 
the chosen algorithm used to collect and report COPD 
exacerbations, and how this is likely to impact upon the 
reported rates. In the UK-based Salford Lung study, which 
reported an exacerbation rate higher than most previous stud-
ies, inclusion criteria were more reflective of daily clinical 
practice than many cohort studies and RCTs in patients with 
COPD. However, the reported exacerbation rates were still 
higher than the DACCORD study, even though both stud-
ies are putatively reflective of primary care populations in 
European countries. In the Salford Lung study, unlike all 
other studies, patients were not involved in the diagnosis of 
exacerbations, rather, passive data collection based on the 
markers of antibiotics and corticosteroid prescription was 
used.5 The consequence of this may have been increased 
diagnosis rates compared with other studies, as in the vast 
majority of studies exacerbations are reported using patient 
recall, which may introduce a recall bias in that patients 
would underreport events.
Are there unreported exacerbations or 
underdiagnosed COPD in Japan?
Underreporting of symptoms is a recognized problem,3 which 
is important since it is associated with a worse quality of life 
and an increased likelihood of hospitalization consequent to 
an exacerbation.41 The Phase III study ATTAIN prospectively 
characterized the levels and impact of reported and unre-
ported exacerbations, comparing the rates obtained using a 
patient diary (Exacerbations of Chronic Pulmonary Disease 
Tool [EXACT®]: a 14-item electronic daily diary completed 
at night) vs an analysis of healthcare resource utilization 
(HCRU) records (including patient diary cards, prescrip-
tion, and hospitalization data).42 The concordance between 
EXACT-identified events and HCRU-identified events was 
poor, with EXACT-identified exacerbation rates double 
that of HCRU-identified events. Moreover, irrespective of 
the method of detection, the rates of reported vs unreported 
events showed a large variation between the different coun-
tries included in the trial.42 The results of this study and oth-
ers have demonstrated that there is poor agreement between 
diary card-reported exacerbations and those identified by 
medical intervention.42,43 Potential underreporting of COPD 
exacerbations could be a factor in the reduced exacerbation 
rates seen in Japan, given the method of data collection used 
to identify exacerbation events.
COPD is also frequently underdiagnosed in the Western 
world, with undiagnosed rates of 50%–86% in an analysis 
of epidemiologic surveys,44 figures that are supported by the 
fact that 6% of adults worldwide have been told that they 
have COPD.38 When considered in combination, these data 
highlight the global issue of unreported “hidden exacerba-
tions”. It is unclear whether this is also the case in Japan.
It is estimated that ∼5.2 million people aged 40 years 
live with COPD in Japan,45 although only 220,000 people 
were receiving treatment for COPD in 2008.46 In Japanese 
patients with moderate to severe COPD enrolled in a random-
ized study of salmeterol/fluticasone vs tiotropium, the rate 
of physician-diagnosed exacerbations was 0.33/person-year 
compared with 1.79/person-year for an algorithm utilizing 
diary-detected exacerbations.9 Thus, underreporting and 
underdiagnosis of COPD exacerbations likely are occurring 
in Japan, but there is no compelling evidence that it is hap-
pening to a greater degree than any other country or region. 
As such, it is unlikely to be a large contributory factor to the 
low rates of exacerbations in Japan.
Conclusion
Reported rates of COPD exacerbations appear to be lower 
in Japan compared with other countries. The difference in 
exacerbation rate between studies appeared greater than 
the difference between Japan and Western countries, likely 
because of disparities between settings, design, and inclu-
sion criteria. Although Japanese patients may complain less 
about their symptoms, this is not currently evidenced in the 
literature. It may be postulated that extrinsic factors such 
as environmental, lifestyle, and better access to health care 
contribute to this lower reported rate, but no evidence was 
found that could support or refute this hypothesis.
However, there may be differences in the diagnostic 
approach to COPD, specifically in relation to patients with 
clinical features of both COPD and asthma, which leads to 
a degree of diagnostic transfer and a reduction in observed 
COPD exacerbation incidence in Japan. There is also direct 
evidence that patients across the world may underreport 
exacerbations, even in the context of a clinical trial, and that 
this underreporting may also exist in Japan. Further studies 
are needed in cohorts that are representative of the general 
population, using improved tools to capture exacerbations in 
increasingly digitally aware patient groups. As exacerbations 
are associated with progression of COPD, it is important 
that incidences of exacerbation are correctly identified and 
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reported to physicians so that patients can receive appropriate 
treatment. Studies in an unselected Japanese population that 
are comparable to studies from the rest of the world in their 
inclusion criteria and methods of exacerbation diagnosis are 
lacking and would allow for an important advancement in 
understanding if they were performed. Understanding the 
reasons why COPD exacerbation rates are lower in Japan 
could help clinicians to recognize and modify treatment 
behaviors, which may lead to improved patient outcomes 
in all populations.
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Supplementary materials
Table S1 Summary of key study design information from cohort studies detailing COPD exacerbation rates in Japan1–9
Study Study design Study center(s), 
recruitment period
Inclusion criteria Definitions of COPD exacerbation
Kyoto cohort 
(Takahashi et al, 
2012)1
Prospective cohort 
study
•	 Kyoto University 
Hospital
•	 September 2006–
August 2008
•	 Male patients with 
COPD
•	 No exacerbation 
history criteria
Prospectively identified using diary cards, 
based on an increase in any two major 
symptoms (dyspnea, sputum purulence, and 
sputum quantity) or an increase in one major 
and one minor symptom (wheeze, sore 
throat, cough, and nasal congestion/discharge) 
for at least 2 consecutive days
Nippon cohort 
(Motegi et al, 
2013)2
Prospective cohort 
study
•	 Nippon Medical 
School Respiratory 
Care Clinic
•	 April–October 2007
•	 Patients with COPD 
(GOLD)
•	 40 years of age
•	 Current or ex-smokers 
(20 pack-years)
•	 No exacerbation 
history criteria
Onset or worsening of more than two 
symptoms (dyspnea, sputum purulence or 
volume, cough, or wheeze) for more than  
2 consecutive days
Kitano cohort 
(Takemura et al, 
2013)3
Prospective, 
pre–post, 
nonequivalent 
group study
•	 Kitano Hospital 
Medical Research 
Institute
•	 November 2006–
December 2010
•	 Patients with COPD 
(GOLD)
•	 Current or ex-smokers 
(10 pack-years)
•	 No change in 
medication for 
3 months before study
•	 No exacerbation 
history criteria
Symptomatic deterioration (dyspnea, cough, 
sputum purulence/volume, or wheeze) that 
required treatment with oral corticosteroids 
and/or antibiotics or hospitalization
Hokkaido 
cohort (Suzuki 
et al, 2014)4
Prospective, 
5-year follow-up, 
observational study
•	 Hokkaido University 
Hospital
•	 May 2003–May 2005
•	 Patients with COPD 
(GOLD)
•	 40 years of age
•	 Current or ex-smokers 
(10 pack-years)
•	 No exacerbation 
1 month prior to study
Symptom definition: worsening or new onset 
of either two major symptoms or one major 
and one minor symptom
Saitama cohort 
(Kurashima et al, 
2015)5
Observational 
study conducted 
to evaluate airway 
structure and 
exacerbation
•	 Saitama 
Cardiovascular and 
Respiratory Center
•	 March–October 2013
•	 Male patients with 
COPD
•	 No exacerbation 
history criteria
Respiratory exacerbations requiring treatment 
with antibiotics and/or steroid
CAP study 
(Matsunaga et al, 
2015)6
Cross-sectional 
study
•	 Multicenter study 
in 15 primary or 
secondary care 
facilities in Japan
•	 Clinical diagnosis of 
COPD
•	 40–95 years of age
•	 No exacerbation in the 
4 weeks prior to the 
survey
An acute event characterized by a worsening 
of respiratory symptoms that was beyond 
normal day-to-day variations and led to a 
change in medication (identified using medical 
records)
Kurume cohort 
(Natori et al, 
2016)7
A 52-week 
prospective 
observational study
•	 Kurume University 
and Chikugo City 
Hospital
•	 Patients with COPD 
(GOLD)
•	 No exacerbation 
4 weeks prior to study 
entry
Increased cough and sputum production, 
a change in sputum color, and worsening 
of dyspnea from a stable state and beyond 
normal day-to-day variations
(Continued)
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Table S1 (Continued)
Study Study design Study center(s), 
recruitment period
Inclusion criteria Definitions of COPD exacerbation
Keio cohort 
(Sato et al, 
2016)8
Prospective 
observational 
cohort study
•	 Keio University and 
affiliated Hospitals
•	 April 2010–
December 2012
•	 Patients with COPD 
(spirometry)
•	 No exacerbation for 
1 month prior to 
enrollment
Moderate COPD: requirement for treatment 
with systemic corticosteroids/antibiotics/both. 
Severe COPD: requiring hospitalization and 
emergency admission for 24 hours
Chiba cohort 
(Takayanagi  
et al, 2017)9
Prospective, 
2-year, 
observational study
•	 Chiba University 
Hospital
•	 May 2012–July 2014
•	 Patients with COPD 
(ATS/eRS)
•	 Current or ex-smokers
•	 No exacerbation 
history criteria
Deterioration of COPD that requires 
antibiotics and/or systemic steroid use
Note: All data reported as mean±SD unless otherwise stated.
Abbreviations: ATS/eRS, American Thoracic Society/european Respiratory Society recommendations; GOLD, Global initiative for chronic Obstructive Lung Disease.
Table S2 Summary of key study design information from RCTs detailing COPD exacerbation rates in Japan10–14
Study Study characteristics Study center(s), 
recruitment period
Inclusion criteria Definitions of COPD 
exacerbation
Furumoto 
et al 
(2008)10
Open-label, randomized, 
controlled study in patients 
with chronic lung disease
•	 Thirteen hospitals in 
Kyushu and Okinawa 
district
•	 November 2001– 
April 2002
•	 Patients with chronic lung 
disease including COPD, 
sequelae of pulmonary 
tuberculosis
•	 Previous exacerbations
Two of the three defined respiratory 
symptoms existed or when one of 
these and one additional symptom, 
such as a fever without any other 
causes or increased cough, was 
present
Sasaki et al 
(2009)11
Randomized, 12-month, 
observer-blind, controlled 
trial
•	 One University Hospital 
and three city hospitals in 
Miyagi prefecture
•	 October 2005–March 2007
•	 Patients with COPD
•	 No exacerbation criteria 
for inclusion or exclusion
Acute and sustained worsening of 
COPD symptoms requiring changes 
to regular treatment
Fukuchi et al 
(2011)12
Randomized, double 
blinded, placebo controlled 
study (UPLIFT)
•	 Multicenter study •	 Patients with COPD
•	 Age 40 years
•	 Post-Fev1% pred: 70%
•	 Post-Fev1/FvC: 70%
•	 Smoking history 10 
pack-years
•	 No exacerbation 4 weeks 
before screening
An increase in or the new onset of 
more than one respiratory symptom 
(cough, sputum, sputum purulence, 
wheezing, or dyspnea) lasting 3 days 
or more and requiring treatment 
with an antibiotic or a systemic 
corticosteroid
Fukuchi et al 
(2016)13
Randomized, double-blind, 
placebo-controlled parallel 
trial
•	 Multicenter study across 
47 medical institutions in 
Japan
•	 August 2012–January 2015
•	 Patients with COPD
•	 Age: 20 to 85 years
•	 Post-Fev1% pred: 80%
•	 Post-Fev1/FvC: 70%
•	 1 exacerbations in the 
previous year
•	 No exacerbation 
7 days prior to drug 
administration
worsening of more than one 
symptom of COPD (cough, sputum 
volume, purulent sputum, or 
breathlessness) leading to a change 
in medication
Jones et al 
(2016)14
Randomized, controlled, 
24-week study assessing 
exacerbations using 
eXACT and physician 
diagnosis (COSMOS-J 
study)
•	 Multicenter study
•	 February 2013– 
September 2015
•	 Patients with COPD 
(GOLD)
•	 Age 40–80 years
•	 Post-Fev1/FvC: 70%
•	 Current or ex-smokers 
(10 pack-years)
Physician diagnosis of exacerbation 
and evaluation of eXACT diary
Note: All data reported as mean±SD unless otherwise stated.
Abbreviations: eXACT, exacerbations of Chronic Pulmonary Disease Tool; GOLD, Global initiative for chronic Obstructive Lung Disease; pred, predicted.
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